MetaVia Inc.

$2.89+53.72%(+$1.01)
TickerSpark Score
63/100
Mixed
100
Valuation
20
Profitability
60
Growth
84
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTVA research report →

52-Week Range11% of range
Low $0.97
Current $2.89
High $19.03

Companywww.metaviatx.com

MetaVia Inc. , a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.

CEO
Hyung Heon Kim
IPO
2016
Employees
9
HQ
Cambridge, MA, US

Price Chart

-61.97% · this period
$16.50$8.73$0.97May 20Nov 18May 20

Valuation

Market Cap
$6.36M
P/E
-1.07
P/S
0.00
P/B
1.55
EV/EBITDA
0.53
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-172.92%
ROIC
-149.42%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-12,973,000 · 52.98%
EPS
$-7.35 · 81.23%
Op Income
$-13,708,000
FCF YoY
36.47%

Performance & Tape

52W High
$19.03
52W Low
$0.97
50D MA
$1.39
200D MA
$5.87
Beta
0.58
Avg Volume
1.53M

Get TickerSpark's AI analysis on MTVA

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jan 23, 26Woodworth Marshall Hother28,000
Jan 23, 26Kim Hyung Heonother32,000
Aug 12, 25Woodworth Marshall Hother14,200
Jun 30, 25Glickman Mark Aother28,147
Jun 30, 25GROVES JASON Lother28,147
Jun 30, 25Tursi James Patrickother28,147
Jun 30, 25STRICKLAND D GORDONother28,147
Jun 30, 25KOVEN ANDREW Iother28,147
Jun 30, 25Salsbury Michaelother28,147
Jun 4, 25Woodworth Marshall Hbuy14,200

Our MTVA Coverage

We haven't published any research on MTVA yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate MTVA Report →

Similar Companies